NASDAQ:JAZZJazz Pharmaceuticals Stock Price, Forecast & News

Jazz Pharmaceuticals' stock was trading at $108.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, JAZZ shares have decreased by 1.3% and is now trading at $106.60. View which stocks have been most impacted by Coronavirus.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Jazz Pharmaceuticals.

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Jazz Pharmaceuticals.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) posted its quarterly earnings data on Tuesday, May, 5th. The specialty pharmaceutical company reported $0.45 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.21 by $0.24. The specialty pharmaceutical company earned $534.73 million during the quarter, compared to the consensus estimate of $544.55 million. Jazz Pharmaceuticals had a net margin of 12.81% and a return on equity of 21.66%. Jazz Pharmaceuticals's quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the business posted $3.67 EPS. View Jazz Pharmaceuticals' earnings history.

Jazz Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided EPS guidance of 11.25-12.50 for the period, compared to the Thomson Reuters consensus estimate of $12.31. The company issued revenue guidance of $2.12-2.26 billion, compared to the consensus revenue estimate of $2.3 billion.

18 brokerages have issued 1-year price targets for Jazz Pharmaceuticals' shares. Their forecasts range from $109.00 to $195.00. On average, they expect Jazz Pharmaceuticals' stock price to reach $157.18 in the next twelve months. This suggests a possible upside of 47.4% from the stock's current price. View analysts' price targets for Jazz Pharmaceuticals.

Media coverage about JAZZ stock has trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Jazz Pharmaceuticals earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Jazz Pharmaceuticals.

Jazz Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 3,740,000 shares, an increase of 32.2% from the June 15th total of 2,830,000 shares. Based on an average daily volume of 660,600 shares, the days-to-cover ratio is currently 5.7 days. Currently, 7.0% of the shares of the company are short sold. View Jazz Pharmaceuticals' Current Options Chain.

Some companies that are related to Jazz Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Visa (V), Bank of America (BAC) and Biogen (BIIB).

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Jazz Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.15%) and Mount Yale Investment Advisors LLC (0.01%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Catherine A Sohn, Finbar Larkin, Kenneth W O'keefe, Matthew P Young, Michael Patrick Miller, Patricia Carr, Patrick G Enright, Paul Treacy, Rick E Winningham, Seamus Mulligan and Suzanne Sawochka Hooper. View institutional ownership trends for Jazz Pharmaceuticals.

JAZZ stock was sold by a variety of institutional investors in the last quarter, including Mount Yale Investment Advisors LLC. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Catherine A Sohn, Finbar Larkin, Kenneth W O'keefe, Michael Patrick Miller, Patricia Carr, and Paul Treacy. View insider buying and selling activity for Jazz Pharmaceuticals.

JAZZ stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for Jazz Pharmaceuticals.

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of JAZZ stock can currently be purchased for approximately $106.60.

Jazz Pharmaceuticals has a market capitalization of $5.90 billion and generates $2.16 billion in revenue each year. The specialty pharmaceutical company earns $523.37 million in net income (profit) each year or $14.60 on an earnings per share basis. Jazz Pharmaceuticals employs 1,620 workers across the globe.

The official website for Jazz Pharmaceuticals is www.jazzpharma.com.

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 011-353-1634-7800 or via email at [email protected]